Immunology and inflammation
Sanofi’s R&D platform building continues with $6bn-plus IGM deal
Phil Taylor
antibody, GM Biosciences, Immunology and inflammation, Oncology, partnering, Sanofi
0 Comment
Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off
Phil Taylor
Bristol-Myers Squibb, etrasimod, Immunology and inflammation, Pfizer, ulcerative colitis, Zeposia
0 Comment
Boehringer’s spesolimab data raises hope for serious skin disease
Phil Taylor
Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab
0 Comment
FDA knocks back Takeda’s blockbuster hope TAK-721
Phil Taylor
eosinophilic oesophagitis, Immunology and inflammation, pipeline, Takeda
0 Comment
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Phil Taylor
chronic spontaneous urticaria, fenebrutinib, Immunology and inflammation, ligelizumab, Novartis, remibrutinib, Roche, Xolair
0 Comment
Flush with COVID cash, Pfizer tables $6.7bn bid for Arena
Phil Taylor
Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, M&A, Pfizer, ulcerative colitis, Zeposia
0 Comment
FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, Immunology and inflammation, Otezla, psoriasis
0 Comment
Strike two for Novartis’ lung cancer antibody canakinumab
Phil Taylor
canakinumab, Immunology and inflammation, lung cancer, Novartis, Oncology
0 Comment